Bulk Manufacturer of Controlled Substances Application: AMRI Rensselaer, Inc., 41517 [2021-16337]
Download as PDF
<![CDATA[
41517
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 145 / Monday, August 2, 2021 / Notices
(11) If you are a producer, an exporter,
or a trade/business association of
producers or exporters of the Subject
Merchandise in any Subject Country,
provide the following information on
your firm’s(s’) operations on that
product during calendar year 2020
(report quantity data in square yards
and value data in U.S. dollars, landed
and duty-paid at the U.S. port but not
including antidumping or
countervailing duties). If you are a
trade/business association, provide the
information, on an aggregate basis, for
the firms which are members of your
association.
(a) Production (quantity) and, if
known, an estimate of the percentage of
total production of Subject Merchandise
in each Subject Country accounted for
by your firm’s(s’) production;
(b) Capacity (quantity) of your firm(s)
to produce the Subject Merchandise in
each Subject Country (that is, the level
of production that your establishment(s)
could reasonably have expected to
attain during the year, assuming normal
operating conditions (using equipment
and machinery in place and ready to
operate), normal operating levels (hours
per week/weeks per year), time for
downtime, maintenance, repair, and
cleanup, and a typical or representative
product mix); and
(c) the quantity and value of your
firm’s(s’) exports to the United States of
Subject Merchandise and, if known, an
estimate of the percentage of total
exports to the United States of Subject
Merchandise from each Subject Country
accounted for by your firm’s(s’) exports.
(12) Identify significant changes, if
any, in the supply and demand
conditions or business cycle for the
Domestic Like Product that have
occurred in the United States or in the
market for the Subject Merchandise in
each Subject Country after 2015, and
significant changes, if any, that are
likely to occur within a reasonably
foreseeable time. Supply conditions to
consider include technology;
production methods; development
efforts; ability to increase production
(including the shift of production
facilities used for other products and the
use, cost, or availability of major inputs
into production); and factors related to
the ability to shift supply among
different national markets (including
barriers to importation in foreign
markets or changes in market demand
abroad). Demand conditions to consider
include end uses and applications; the
existence and availability of substitute
products; and the level of competition
among the Domestic Like Product
produced in the United States, Subject
Merchandise produced in each Subject
VerDate Sep<11>2014
17:21 Jul 30, 2021
Jkt 253001
Country, and such merchandise from
other countries.
(13) (OPTIONAL) A statement of
whether you agree with the above
definitions of the Domestic Like Product
and Domestic Industry; if you disagree
with either or both of these definitions,
please explain why and provide
alternative definitions.
Authority: This proceeding is being
conducted under authority of title VII of
the Tariff Act of 1930; this notice is
published pursuant to § 207.61 of the
Commission’s rules.
By order of the Commission.
Issued: July 26, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–16239 Filed 7–30–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Bulk Manufacturer of Controlled
Substances Application: AMRI
Rensselaer, Inc.
Drug Enforcement
Administration, Justice.
AGENCY:
AMRI Rensselaer, Inc., has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 1, 2021. Such persons
may also file a written request for a
hearing on the application on or before
October 1, 2021.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on May 31, 2021, AMRI
Rensselaer Inc., 33 Riverside Avenue,
Rensselaer, New York 12144–2951,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Fmt 4703
7360
7370
1100
1205
2270
8333
I
I
II
II
II
II
9050
9143
9150
9193
9300
9801
II
II
II
II
II
II
The company plans to manufacture
the above controlled substances as bulk
active pharmaceutical ingredients (API)
for use in product development and for
distribution to its customers. In
reference to drug codes 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Sfmt 4703
[FR Doc. 2021–16337 Filed 7–30–21; 8:45 am]
BILLING CODE P
[OMB Number 1122–0027]
Notice of application.
Frm 00085
Schedule
DEPARTMENT OF JUSTICE
SUMMARY:
PO 00000
Marihuana ........................
Tetrahydrocannabinols ....
Amphetamine ..................
Lisdexamfetamine ...........
Pentobarbital ...................
ANPP (4-Anilino-Nphenethyl-4-piperidine).
Codeine ...........................
Oxycodone ......................
Hydromorphone ...............
Hydrocodone ...................
Morphine ..........................
Fentanyl ...........................
Drug
code
William T. McDermott,
Assistant Administrator.
[Docket No. DEA–877]
ACTION:
Controlled substance
Agency Information Collection
Activities; Proposed eCollection
Requested; Extension of a Currently
Approved Collection
Office on Violence Against
Women, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Office on Violence
Against Women (OVW), Department of
Justice, will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
October 1, 2021.
FOR FURTHER INFORMATION CONTACT:
Written comments and/or suggestion
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to Cathy Poston,
Office on Violence Against Women, at
202–514–5430 or Catherine.poston@
usdoj.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
SUMMARY:
E:\FR\FM\02AUN1.SGM
02AUN1
]]>Agencies
[Federal Register Volume 86, Number 145 (Monday, August 2, 2021)]
[Notices]
[Page 41517]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16337]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-877]
Bulk Manufacturer of Controlled Substances Application: AMRI
Rensselaer, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: AMRI Rensselaer, Inc., has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before October 1, 2021.
Such persons may also file a written request for a hearing on the
application on or before October 1, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on May 31, 2021, AMRI Rensselaer Inc., 33 Riverside
Avenue, Rensselaer, New York 12144-2951, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana............................... 7360 I
Tetrahydrocannabinols................... 7370 I
Amphetamine............................. 1100 II
Lisdexamfetamine........................ 1205 II
Pentobarbital........................... 2270 II
ANPP (4-Anilino-N-phenethyl-4- 8333 II
piperidine).
Codeine................................. 9050 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Hydrocodone............................. 9193 II
Morphine................................ 9300 II
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to manufacture the above controlled substances as
bulk active pharmaceutical ingredients (API) for use in product
development and for distribution to its customers. In reference to drug
codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs as synthetic. No other activities
for these drug codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-16337 Filed 7-30-21; 8:45 am]
BILLING CODE P
